You're Hydrating Well and Still Getting Kidney Stones. Here's the Biological Reason.

SLC34A1 codes for a sodium-phosphate cotransporter that sits on the surface of kidney tubule cells. Its job is to pull phosphate out of the filtrate and back into the bloodstream, preventing phosphate loss in urine. Without this transporter working properly, you would lose phosphate continuously and develop mineral imbalances.

Variants in SLC34A1 disrupt this transporter’s efficiency. Roughly 5-10% of the population carries a variant that reduces phosphate reabsorption. When this happens, phosphate starts accumulating in your urine instead of being reclaimed by your blood. Urine becomes supersaturated with phosphate, and stone formation becomes likely.

You don’t feel high urinary phosphate. You won’t see it on standard labs. What you experience is recurrent kidney stones, often made of calcium phosphate or struvite. Prevention requires actively managing dietary phosphate and potentially adjusting how your kidneys handle this mineral.

UMOD codes for uromodulin, a protein secreted into urine by kidney tubule cells. Uromodulin coats the inner surface of the urinary tract like a protective layer. It prevents bacteria from sticking to cells, and it also regulates the crystallization of minerals. It is your kidneys’ own antimicrobial and stone-prevention system.

Variants in UMOD impair uromodulin secretion. Roughly 10-20% of the population carries a variant that reduces how much uromodulin your kidneys can produce. With less uromodulin coating your urinary tract, minerals crystallize more easily, and bacteria have an easier time establishing infections that can lead to stone formation. You become vulnerable to both UTIs and kidney stones simultaneously.

Many people with UMOD variants form stones even while maintaining excellent hydration. They also experience recurrent UTIs. The mechanism is simple: your first line of defense is weak, and both bacteria and minerals take advantage. Prevention requires active management of both infection risk and crystal formation.

VDR codes for the vitamin D receptor, a protein that sits inside cells and responds when vitamin D activates it. The VDR controls how your body absorbs calcium from food, how much calcium your kidneys filter, and how your immune system responds to infection. It is central to both mineral metabolism and kidney defense.

Common VDR variants change the sensitivity of this receptor to vitamin D signaling. Depending on which variant you carry, your cells may respond more or less strongly to circulating vitamin D. Roughly 30-40% of the population carries variants that reduce VDR responsiveness. When VDR signaling is weak, your kidneys become less efficient at managing calcium, and your immune defense against UTIs weakens. Both mechanisms increase kidney stone risk.

People with certain VDR variants often develop stones despite adequate vitamin D levels, because the problem is not vitamin D availability but cellular responsiveness to it. They also tend to have more frequent UTIs. The consequence is a double burden: mineral imbalance plus infection-driven stone formation.

MTHFR codes for methylenetetrahydrofolate reductase, an enzyme that converts dietary folate into its active form, methylfolate. This active form is needed for hundreds of cellular processes, including DNA synthesis, cellular repair, and the metabolism of homocysteine, an amino acid that accumulates when folate metabolism is impaired.

The MTHFR C677T variant, carried by roughly 40% of the population, reduces enzyme efficiency by 40-70%. When MTHFR is impaired, homocysteine accumulates in your blood and urine, and homocysteine itself promotes kidney stone formation by altering mineral balance. Additionally, impaired folate metabolism weakens cellular repair processes in your kidney tubules, making them more vulnerable to crystal formation.

You won’t feel elevated homocysteine. It will not show up on routine bloodwork unless your doctor specifically tests for it. What you will experience is recurrent stones despite good hydration, often paired with fatigue, brain fog, or mood changes (other signs of impaired methylation). Prevention requires restoring folate metabolism.

AGXT codes for alanine-glyoxylate aminotransferase, an enzyme in your liver that breaks down oxalate, a compound found in many foods. Oxalate cannot be excreted directly by your body; it must be converted into other compounds by the AGXT enzyme. Without adequate AGXT activity, oxalate accumulates and is filtered through your kidneys into the urine.

Loss-of-function variants in AGXT are rare, but when they occur, they cause primary hyperoxaluria, a condition in which oxalate accumulates to extremely high levels. People with AGXT loss-of-function variants form calcium oxalate stones frequently and often from childhood. Serum oxalate and urinary oxalate are dramatically elevated. Standard dietary oxalate restriction does little because your body cannot metabolize oxalate properly regardless of intake.

If you have primary hyperoxaluria, kidney stones are not occasional but recurrent and severe. Many people with this condition form multiple stones per year and progress to kidney disease. This is the most serious genetic kidney stone risk, and it requires aggressive specialized management.

SLC7A9 codes for a transporter protein that sits on kidney tubule cells and pumps cystine (a molecule made from two amino acids linked together) back into the bloodstream. Normally, when your kidneys filter amino acids, the transporters reclaim them so they are not lost in urine. Cystine is handled by SLC7A9 specifically.

Loss-of-function variants in SLC7A9 cause cystinuria, a condition in which cystine cannot be reabsorbed and accumulates in urine to extremely high levels. This is rare, but when it occurs, cystine becomes so concentrated in urine that it precipitates directly, forming cystine stones that are notoriously difficult to dissolve and prevent. Roughly 1 in 10,000 people have cystinuria, but it is the most aggressive genetic cause of kidney stones.

If you have cystinuria, stones form frequently and early in life. Cystine stones are hard, resistant to standard prevention, and prone to recurrence. Many people with cystinuria form multiple stones in childhood and continue throughout life. This requires highly specialized management and often prophylactic medication to prevent stone formation entirely.